Embera Neurotherapeutics, Inc. is a specialty pharmaceutical company based in Sudbury, MA, that is dedicated to developing innovative treatments for addiction. Their groundbreaking medication, EMB-001, targets the stress response system to reduce cravings and loss of control associated with addiction. By uniquely targeting multiple pathways, EMB-001 aims to maximize efficacy and contribute to long-term abstinence and recovery for a wide range of addictions.
Embera Neurotherapeutics has recently completed Series B financing and received grants to advance EMB-001 into Phase 2 clinical studies for cocaine use disorder and smoking cessation. Led by CEO Bob Linke and Chief Medical Officer Mike Detke, the company is committed to redefining addiction treatment and addressing the burden of addiction on society. With a proactive approach to stimulant use and a focus on developing a new approach to addiction treatment, Embera Neurotherapeutics is at the forefront of revolutionizing the field of addiction medicine.
Generated from the website